{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:37:19Z","timestamp":1791463039353,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00775-z","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:15:54Z","timestamp":1759230954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acquired HIV-1 drug resistance to reverse transcriptase and protease inhibitors among people failing antiretroviral therapy in Cameroon and implications for future treatment options"],"prefix":"10.1186","volume":"22","author":[{"given":"Joseph","family":"Fokam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tekoh Tatiana","family":"Anim-Keng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Thumamo","family":"Pokam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins Ambe","family":"Chenwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude Christelle","family":"Ka\u2019e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezechiel Ngoufack Jagni","family":"Semengue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile Estelle Gr\u00e2ce","family":"Beloumou Angong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desire","family":"Takou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Djupsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi-Karell","family":"Etame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evariste","family":"Molimbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogers","family":"Ajeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Cecile Z-K","family":"Bissek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Colizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo-Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory-Edie","family":"Halle-Ekane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"775_CR1","unstructured":"HIV data and statistics. https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics (accessed 27 November 2023)."},{"key":"775_CR2","unstructured":"HIV. https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids (accessed 27 November 2023)."},{"key":"775_CR3","unstructured":"HIV Country Profiles. https:\/\/cfs.hivci.org\/index.html (accessed 27 November 2023)."},{"key":"775_CR4","doi-asserted-by":"publisher","unstructured":"Temereanca A, Ruta S. Strategies to overcome HIV drug resistance-current and future perspectives. Front Microbiol. 2023;14. https:\/\/doi.org\/10.3389\/fmicb.2023.1133407. (accessed 27 October 2023).","DOI":"10.3389\/fmicb.2023.1133407"},{"key":"775_CR5","unstructured":"Global HIV. July & AIDS statistics \u2014 Fact sheet. https:\/\/www.unaids.org\/en\/resources\/fact-sheet (accessed 11 2024)."},{"key":"775_CR6","doi-asserted-by":"crossref","unstructured":"Bekolo CE, Ndeso SA, Moifo LL, et al. Universal test and treat in Cameroon: a comparative retrospective analysis of mortality and loss to follow-up before and after a strategic change inapproach to HIV care. Pan Afr Med J; 45. Epub ahead of print 31 August 2023. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10656581\/","DOI":"10.11604\/pamj.2023.45.191.40448"},{"key":"775_CR7","doi-asserted-by":"crossref","unstructured":"Fokam J, Chenwi CA, Tala V, et al. Pre-Treatment HIV Drug Resistance and GeneticDiversity in Cameroon: Implications for First-Line Regimens. Viruses 2023; 15: 1458.","DOI":"10.3390\/v15071458"},{"key":"775_CR8","unstructured":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approachhttps:\/\/www.who.int\/publications\/i\/item\/9789240031593"},{"key":"775_CR9","unstructured":"HIV Drug Resistance Report 2021. Tech Rep."},{"key":"775_CR10","doi-asserted-by":"crossref","unstructured":"TchouwaGF, Eymard-Duvernay S, Cournil A, et al. Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon. EClinicalMedicine2018; 1: 21\u201327.","DOI":"10.1016\/j.eclinm.2018.06.005"},{"key":"775_CR11","doi-asserted-by":"crossref","unstructured":"BainLE, Tarkang EE, Ebuenyi ID, et al. The HIV\/AIDS pandemic will not end by the year 2030 in low and middle income countries. Pan Afr Med J 2019; 32: 67.","DOI":"10.11604\/pamj.2019.32.67.17580"},{"key":"775_CR12","unstructured":"Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy - World| ReliefWeb(2022, accessed 8 February 2024). https:\/\/reliefweb.int\/report\/world\/sentinel-surveys-acquired-hiv-resistance-dolutegravir-among-people-receiving-dolutegravir-containing-antiretroviral-therapy"},{"key":"775_CR13","doi-asserted-by":"crossref","unstructured":"Fokam J, Chenwi CA, Takou D, et al. LaboratoryBased Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens. Viruses 2023; 15: 1683.","DOI":"10.3390\/v15081683"},{"key":"775_CR14","doi-asserted-by":"crossref","unstructured":"Fokam J, Takou D, Njume D, et al. Alarming rates of virological failure and HIV-1drug resistance amongst adolescents living with perinatal HIV in both urban andrural settings: evidence from the EDCTP READY-study in Cameroon. HIV Med 2021; 22: 567\u2013580.","DOI":"10.1111\/hiv.13095"},{"key":"775_CR15","unstructured":"Monthly Newsletter N\u00b0 003 June 2022: Cameroon on track to meet 2030 hiv\/aids targets| CNLS https:\/\/cnls.cm\/site\/en\/blog\/monthly-newsletter-ndeg-003-june-2022-cameroon-track-meet-2030-hivaids-targets"},{"key":"775_CR16","unstructured":"Laboratory-based survey of acquired HIV drug resistance using remnant viral load specimens(accessed 15 November 2022). https:\/\/www.who.int\/publications-detail-redirect\/9789240025417"},{"key":"775_CR17","doi-asserted-by":"crossref","unstructured":"Fokam J, Ngoufack Jagni Semengue E,Molimbou E, et al. Evaluation of Circulating and Archived HIV-1Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings. Microbiol Spectr 2022; 10: e03420-22.","DOI":"10.1128\/spectrum.03420-22"},{"key":"775_CR18","unstructured":"Webinar 22 November 2022 - Surveillance of acquired HIV resistance to dolutegravir among people receiving dolutegravir-based antiretroviral therapy with unsuppressed viral loadhttp:\/\/www.who.int\/news-room\/events\/detail\/2022\/11\/22\/default-calendar\/webinar-22nov2022-surveillance-of-acquired-hiv-resistance-to-dgt"},{"key":"775_CR19","doi-asserted-by":"crossref","unstructured":"SemengueENJ, Armenia D, Inzaule S, et al. Baseline integrase drug resistance mutationsand conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. J Antimicrob Chemother 2021; 76: 1277\u20131285.","DOI":"10.1093\/jac\/dkab004"},{"key":"775_CR20","doi-asserted-by":"crossref","unstructured":"Fokam J, Salpini R, Santoro MM, et al. Performanceevaluation of an in-house human immunodeficiency virus type-1 protease-reversetranscriptase genotyping assay in Cameroon. Arch Virol 2011; 156: 1235\u20131243.","DOI":"10.1007\/s00705-011-0982-3"},{"key":"775_CR21","doi-asserted-by":"crossref","unstructured":"WoodsCK, Brumme CJ, Liu TF, et al. Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool. J Clin Microbiol 2012; 50: 1936\u20131942.","DOI":"10.1128\/JCM.06689-11"},{"key":"775_CR22","doi-asserted-by":"crossref","unstructured":"Fabeni L, Berno G, Fokam J, et al. ComparativeEvaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.J Clin Microbiol 2017; 55: 2827\u20132837.","DOI":"10.1128\/JCM.00656-17"},{"key":"775_CR23","unstructured":"MINSANTE.NATIONAL GUIDELINES FOR HIV\/AIDSPREVENTION AND MANAGEMENT IN CAMEROON2024."},{"key":"775_CR24","doi-asserted-by":"crossref","unstructured":"Ngo-Giang-Huong N, Aghokeng AF. HIV Drug Resistance in Resource-limited Countries: Threat for HIV Elimination. EClinicalMedicine 2019; 9: 3\u20134","DOI":"10.1016\/j.eclinm.2019.03.013"},{"key":"775_CR25","doi-asserted-by":"crossref","unstructured":"Takou D, Fokam J, Teto G, et al. HIV-1 drug resistance testing is essential forheavily-treated patients switching from first- to second-line regimens inresource-limited settings: evidence from routine clinical practice in Cameroon. BMC Infect Dis 2019; 19: 246.","DOI":"10.1186\/s12879-019-3871-0"},{"key":"775_CR26","doi-asserted-by":"crossref","unstructured":"Musana H, Ssensamba JT, Nakafeero M, et al. Predictors of failure on second-lineantiretroviral therapy with protease inhibitor mutations in Uganda.AIDS Res Ther 2021; 18: 17.","DOI":"10.1186\/s12981-021-00338-y"},{"key":"775_CR27","unstructured":"Paton NI, Kityo C, Thompson J, et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised,open-label, EARNEST trial. Lancet HIV 2017; 4: e341\u2013e348."},{"key":"775_CR28","doi-asserted-by":"crossref","unstructured":"Pennings PS. HIV Drug Resistance: Problems and Perspectives. Infect Dis Rep; 5. Epub ahead of print 6 June 2013. DOI: 10.4081\/idr.2013.s1.e5.","DOI":"10.4081\/idr.2013.s1.e5"},{"key":"775_CR29","unstructured":"WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoringhttps:\/\/www.who.int\/news\/item\/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring"},{"key":"775_CR30","doi-asserted-by":"crossref","unstructured":"Ezenwosu IL, Onu JU, Chukwuma UV, et al. Effectof dolutegravir-based drug combinations on the level of medication adherenceand viral load among adolescents living with HIV in resource-limited setting: a pre-post design. Int J Adolesc Med Health 2023; 35: 457\u2013465.","DOI":"10.1515\/ijamh-2023-0082"},{"key":"775_CR31","doi-asserted-by":"crossref","unstructured":"FokamJ, Nka AD, Mamgue Dzukam FY, et al. Viral suppression in the era of transitionto dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics. Medicine (Baltimore) 2023; 102: e33737.","DOI":"10.1097\/MD.0000000000033737"},{"key":"775_CR32","doi-asserted-by":"crossref","unstructured":"Konu YR, Takassi E, Peytavin G, et al. Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir (DTG)-Based Regimen in Togo. Clin Infect Dis 2024; ciae278.","DOI":"10.1093\/cid\/ciae278"},{"key":"775_CR33","doi-asserted-by":"crossref","unstructured":"Jary A, Marcelin A-G, Charpentier C, etal. M184V\/I does not impact the efficacy of abacavir\/lamivudine\/dolutegravir use as switch therapy in virologically suppressed patients. J Antimicrob Chemother 2020; 75: 1290\u20131293.","DOI":"10.1093\/jac\/dkaa019"},{"key":"775_CR34","doi-asserted-by":"crossref","unstructured":"Kandeel M. The impact of the M184V resistance mutation on treatment outcomes inpatients with HIV infection: a systematic review and meta-analysis. AIDS Rev 2023; 26: 136\u2013144.","DOI":"10.24875\/AIDSRev.23000002"},{"key":"775_CR35","doi-asserted-by":"crossref","unstructured":"Ursenbach A, Ruch Y, Hoellinger B, et al. Two Cases of Viral Re-suppression After M184V +R263K Selection on Dolutegravir\/Lamivudine Without Treatment Modification. Clin Infect Dis 2024; ciae006.","DOI":"10.1093\/cid\/ciae006"},{"key":"775_CR36","doi-asserted-by":"crossref","unstructured":"Pared es R, Sagar M, Marconi VC, et al. In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant HumanImmunodeficiency Virus Type 1 in the Absence of Lamivudine. J Virol 2009; 83: 2038\u20132043.","DOI":"10.1128\/JVI.02154-08"},{"key":"775_CR37","doi-asserted-by":"crossref","unstructured":"Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidineanalogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10: 791\u2013802.","DOI":"10.1177\/135965350501000705"},{"key":"775_CR38","doi-asserted-by":"crossref","unstructured":"WangY, Xing H, Liao L, et al. The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy. AIDS Res Ther 2014; 11: 36.","DOI":"10.1186\/1742-6405-11-36"},{"key":"775_CR39","doi-asserted-by":"crossref","unstructured":"Nachega JB, Scarsi KK, Gandhi M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV 2023; 10: e332\u2013e342.","DOI":"10.1016\/S2352-3018(23)00051-6"},{"key":"775_CR40","doi-asserted-by":"crossref","unstructured":"Landovitz RJ, Hanscom BS, Clement ME, etal. Efficacy and safety of long-acting cabotegravir compared with dailyoral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infectionin cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV 2023; 10: e767\u2013e778.","DOI":"10.1016\/S2352-3018(23)00261-8"},{"key":"775_CR41","doi-asserted-by":"crossref","unstructured":"Orkin C, Schapiro JM, Perno CF, et al. ExpandedMultivariable Models to Assist Patient Selection for Long-Acting Cabotegravir +Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure. Clin Infect Dis Off Publ Infect Dis Soc Am 2023; 77: 1423\u20131431.","DOI":"10.1093\/cid\/ciad370"},{"key":"775_CR42","doi-asserted-by":"crossref","unstructured":"Kityo C, Mambule IK, Musaazi J, et al. Switch to long-acting cabotegravir andrilpivirine in virologically suppressed adults with HIV in Africa (CARES): week48 results from a randomised, multicentre, open-label, non-inferiority trial. LancetInfect Dis. Epub ahead of print 28 May 2024. DOI:10.1016\/S1473-3099(24)00289-5.","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"775_CR43","doi-asserted-by":"crossref","unstructured":"de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials. AIDS Res Hum Retroviruses 2008; 24: 379\u2013388.","DOI":"10.1089\/aid.2007.0173"},{"key":"775_CR44","unstructured":"Fokam J, Semengue ENJ, Armenia D, et al. High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries. undefined, (2021, accessed 5 September 2022) https:\/\/www.semanticscholar.org\/paper\/High-performance-of-integrase-genotyping-on-diverse-Fokam-Semengue\/419750f361361825c7f98b3ede22382126127cd7"},{"key":"775_CR45","unstructured":"HIV drug resistance to integrase inhibitors in low- and middle-income countries| Nature Medicine, (accessed 6 May 2025) https:\/\/www.nature.com\/articles\/s41591-023-02763-0#ethics"},{"key":"775_CR46","unstructured":"Ngoufack Jagni Semengue E, Fokam J, EtameN-K, et al. Dolutegravir-based Regimen Ensures High Virological Success despite prior Exposure to Efavirenz-based First-Line ART in Cameroon: An Evidence of a Successful Transition Model. Submitt Viruses J."},{"key":"775_CR47","doi-asserted-by":"crossref","unstructured":"Armenia D, Santoro MM, Charpentier C, et al.Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings. J Antimicrob Chemother 2023; 78: 1415\u20131422.","DOI":"10.1093\/jac\/dkad101"},{"key":"775_CR48","unstructured":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine pluseither zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial - The Lancet HIV https:\/\/www.thelancet.com\/journals\/lanhiv\/article\/PIIS2352-3018(22)00092-3\/fulltext(accessed 16 August 2024)"},{"key":"775_CR49","doi-asserted-by":"crossref","unstructured":"Chenwi CA, Nayang Mundo RA, Nka AD, etal. Plasma Viral Load of 200 Copies\/mL is a Suitable Threshold to DefineViral Suppression and HIV Drug Resistance Testing in Low- and Middle-IncomeCountries: Evidence From a Facility-Based Study in Cameroon. J Int Assoc Provid AIDS Care JIAPAC 2024; 23: 23259582241306484.","DOI":"10.1177\/23259582241306484"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:16:12Z","timestamp":1759230972000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00775-z","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance was obtained from the University of Buea, Faculty of Health Sciences (FHS) Institutional Review Board (Ref. N\u00b0 2023\/1945-01\/UB\/SG\/IRB\/FHS), administrative authorization obtained from the Director of CIRCB (Ref. N\u00b0 2112\/016L\/CIRCB\/DIR\/CL). A certified module on research ethics, the Training and Resources in Research Ethics Evaluation (TRREE-) was completed. The study was conducted according to the ethical principles outlined in the Declaration of Helsinki. Consent was waived as the research was carried out on stored samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}